Jinan Zhuocheng Bio-Tech Co., Ltd.

An extreme heatwave and widespread power grid failure in Punjab's Barnala industrial zone have disrupted operations at the core manufacturing facility of IOL Chemicals and Pharmaceuticals Limited (IOLCP), one of the world's largest producers of ibuprofen active pharmaceutical ingredients (APIs). The incident has drawn industry attention to the resilience of the global ibuprofen supply chain and its potential impact on API availability.

Global Ibuprofen API Supply Faces Potential Disruption

Global ibuprofen API production is concentrated among a handful of manufacturers, including India's IOL Chemicals, China's Xinhua Pharmaceutical, India's Solara Active Pharma Sciences, China's Hubei Hendi Pharmaceutical, Germany's BASF, and SI Group in the United States.

IOL's Barnala manufacturing complex is regarded as one of the world's largest ibuprofen API production sites, with an annual capacity exceeding 12,000 metric tons. The facility operates an integrated manufacturing chain from chemical intermediates to finished APIs and supplies customers in more than 50 countries.

Although the company operates its own captive power and cogeneration facilities, the large-scale regional power outage has reportedly affected utilities, logistics coordination, and supporting infrastructure, making it difficult for production to return to full capacity in the short term. Industry observers believe that if the disruption continues, global ibuprofen API supply could tighten significantly.

Chinese API Manufacturers May Benefit from Increased Export Demand

China is the world's second-largest producer of ibuprofen APIs and maintains a well-established manufacturing base. Domestic supply is primarily supported by leading manufacturers such as Xinhua Pharmaceutical and Hubei Hendi Pharmaceutical, making the Chinese finished dosage market relatively less dependent on imports.

However, the international market presents a different picture. As one of the world's major exporters of ibuprofen APIs, China could see increased overseas inquiries if supply constraints persist in India. Higher export demand may strengthen pricing power for qualified Chinese manufacturers serving global pharmaceutical companies.

Previous market disruptions have demonstrated the sensitivity of ibuprofen API pricing to changes in global supply. During earlier periods of production constraints, international API prices increased rapidly as buyers sought alternative suppliers.

Certified Chinese Producers Could Capture Additional Market Share

Industry analysts suggest that Chinese manufacturers with international regulatory approvals may be well positioned to benefit if the Indian production disruption extends beyond the short term.

Leading Chinese suppliers possess manufacturing scale as well as regulatory certifications from major international markets, enabling them to respond quickly to increased global demand. As international buyers diversify procurement sources, export opportunities for Chinese API producers may continue to expand.

Meanwhile, manufacturers of finished ibuprofen formulations that rely heavily on externally sourced APIs could face higher raw material costs should international API prices remain elevated. Nevertheless, the impact on China's domestic pharmaceutical market is expected to remain limited in the near term due to the country's relatively self-sufficient supply structure.

Extreme Weather Highlights Supply Chain Resilience Challenges

The disruption at IOL's flagship facility underscores the growing vulnerability of global pharmaceutical supply chains to extreme weather events, energy infrastructure risks, and regional disruptions.

As governments and pharmaceutical companies increasingly prioritize supply chain resilience, diversified sourcing and manufacturing capacity are becoming strategic priorities across the industry.

For China's pharmaceutical sector, the incident also highlights the value of a comprehensive manufacturing ecosystem, stable production capacity, and internationally compliant quality systems. Companies capable of ensuring reliable supply while meeting global regulatory standards are expected to play an increasingly important role in the evolving global API market.